TELO — Telomir Pharmaceuticals Balance Sheet
0.000.00%
- $50.68m
- $49.93m
Annual balance sheet for Telomir Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0 | 0.001 | 0.001 | 1.27 |
| Net Total Receivables | — | — | 0.13 | — |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 0 | 0.049 | 0.435 | 1.32 |
| Other Long Term Assets | ||||
| Total Assets | 0 | 0.049 | 4.77 | 1.32 |
| Payable / Accrued | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.138 | 0.986 | 1.34 | 0.681 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | 0.138 | 0.986 | 1.34 | 0.681 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | -0.138 | -0.937 | 3.44 | 0.643 |
| Total Liabilities & Shareholders' Equity | 0 | 0.049 | 4.77 | 1.32 |
| Total Common Shares Outstanding |